Full Press Release Details
MEREO BIOPHARMA GROUP PLC
Condensed Consolidated Statements of Comprehensive (Loss)/Income
| Notes | Six months ended June 30, 2022 '000 | Six months ended June 30, 2021 '000 | ||||||||
| Revenue | 3 | - | 36,464 | |||||||
| Cost of revenue | 3 | 352 | ( 18,137 | ) | ||||||
| Research and development expenses | ( 13,322 | ) | ( 9,858 | ) | ||||||
| Administrative expenses | ( 8,840 | ) | ( 8,673 | ) | ||||||
| Operating loss | ( 21,810 | ) | ( 204 | ) | ||||||
| Finance income | 4 | 173 | 1 | |||||||
| Finance costs | 4 | ( 1,859 | ) | ( 1,987 | ) | |||||
| Changes in the fair value of financial instruments | 4 | 1,210 | 14,363 | |||||||
| Net foreign exchange gain/(loss) | 1,582 | ( 1,269 | ) | |||||||
| Other income and expenses | 5 | 811 | - | |||||||
| (Loss)/profit before tax | ( 19,893 | ) | 10,904 | |||||||
| Taxation | 735 | 1,184 | ||||||||
| (Loss)/profit for the period, attributable to equity holders of the parent | ( 19,158 | ) | 12,088 | |||||||
| Items that may be reclassified subsequently to profit or loss: | ||||||||||
| Currency translation of foreign operations | ( 1,775 | ) | ( 26 | ) | ||||||
| Total comprehensive (loss)/income for the period, attributable to equity holders of the parent | ( 20,933 | ) | 12,062 | |||||||
| Basic (loss)/profit per share for the period (in ) | 6 | ( 0.03 | ) | 0.02 | ||||||
| Diluted loss per share for the period (in ) | 6 | ( 0.03 | ) | 0.00 |
The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.
MEREO BIOPHARMA GROUP PLC
Condensed Consolidated Balance Sheets
| Notes | June 30, 2022 '000 | December 31, 2021 '000 | ||||||||
| Assets | ||||||||||
| Non-current assets | ||||||||||
| Property, plant and equipment | 7 | 2,114 | 2,530 | |||||||
| Intangible assets | 8 | 24,116 | 24,564 | |||||||
| 26,230 | 27,094 | |||||||||
| Current assets | ||||||||||
| Prepayments | 2,741 | 2,799 | ||||||||
| R&D tax credits | 740 | - | ||||||||
| Other taxes receivable | 900 | 809 | ||||||||
| Other receivables | 1,010 | 1,419 | ||||||||
| Cash and short-term deposits | 76,415 | 94,296 | ||||||||
| 81,806 | 99,323 | |||||||||
| Total assets | 108,036 | 126,417 | ||||||||
| Equity and liabilities | ||||||||||
| Non-current liabilities | ||||||||||
| Provisions | 10 | 1,389 | 1,320 | |||||||
| Convertible loan notes | 11 | - | 14,384 | |||||||
| Warrant liability | 1 2 | 222 | 8,336 | |||||||
| Lease liability | 1,456 | 1,754 | ||||||||
| Other liabilities | 177 | 80 | ||||||||
| 3,244 | 25,874 | |||||||||
| Current liabilities | ||||||||||
| Trade and other payables | 2,821 | 2,499 | ||||||||
| Accruals | 5,088 | 3,826 | ||||||||
| Current tax liabilities | - | 1,522 | ||||||||
| Provisions | 10 | 2,945 | 2,803 | |||||||
| Convertible loan notes | 11 | 15,952 | - | |||||||
| Warrant liability | 1 2 | 6,904 | - | |||||||
| Lease liability | 580 | 622 | ||||||||
| Other liabilities | 3 | 917 | 1,269 | |||||||
| 35,207 | 12,541 | |||||||||
| Total liabilities | 38,451 | 38,415 | ||||||||
| Net assets | 69,585 | 88,002 | ||||||||
| Equity | ||||||||||
| Issued capital | 9 | 1,755 | 1,755 | |||||||
| Share premium | 9 | 247,460 | 247,460 | |||||||
| Other capital reserves | 9 | 132,269 | 129,835 | |||||||
| Employee Benefit Trust shares | ( 1,058 | ) | ( 1,140 | ) | ||||||
| Other reserves | 7,401 | 7,401 | ||||||||
| Accumulated losses | ( 316,126 | ) | ( 296,968 | ) | ||||||
| Translation reserve | ( 2,116 | ) | ( 341 | ) | ||||||
| Total equity | 69,585 | 88,002 |
The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.
MEREO BIOPHARMA GROUP PLC
Condensed Consolidated Statements of Cash Flows
| Notes | Six months ended June 30, 2022 '000 | Six months ended June 30, 2021 '000 | ||||||||||
| Operating activities | ||||||||||||
| (Loss)/profit before tax | ( 19,893 | ) | 10,904 | |||||||||
| Adjustments to reconcile (loss)/profit to net cash flows from operating activities | ||||||||||||
| - Depreciation and impairment of property, plant and equipment | 7 | 436 | 260 | |||||||||
| - Share-based payment expense | 9 | 2,446 | 1,760 | |||||||||
| - Net foreign exchange (gain)/loss | ( 2,100 | ) | 1,269 | |||||||||
| - Increase in provisions and other liabilities | 10 | 307 | 1,513 | |||||||||
| - Finance income | 4 | ( 173 | ) | ( 1 | ) | |||||||
| - Finance costs | 4 | 1,696 | 1,915 | |||||||||
| - Changes in the fair value of financial instruments | 4 | ( 1,210 | ) | ( 14,363 | ) | |||||||
| - Other income and expenses | 5 | ( 811 | ) | - | ||||||||
| - Out-license of intangible asset | - | 9,457 | ||||||||||
| - Other non-cash movements | 330 | - | ||||||||||
| Working capital adjustments | ||||||||||||
| - Decrease/(increase) in receivables and prepayments | 331 | ( 1,675 | ) | |||||||||
| - Increase/(decrease) in trade and other payables and accruals | 1,364 | ( 1,137 | ) | |||||||||
| Taxation | ( 1,529 | ) | - | |||||||||
| Net cash flows (used in)/from operating activities | ( 18,806 | ) | 9,902 | |||||||||
| Investing activities | ||||||||||||
| Purchase of property, plant and equipment | 7 | ( 10 | ) | - | ||||||||
| Proceeds from intangible asset | 5 | 1,484 | - | |||||||||
| Payments to CVR holders | 5 | ( 673 | ) | - | ||||||||
| Interest earned | 4 | 173 | 1 | |||||||||
| Net cash flows from investing activities | 974 | 1 | ||||||||||
| Financing activities | ||||||||||||
| Proceeds from issuance of ordinary shares | - | 78,532 | ||||||||||
| Transaction costs on issuance of shares | - | ( 234 | ) | |||||||||
| Proceeds from TAP agreement | 153 | - | ||||||||||
| Payment of lease liabilities | ( 445 | ) | ( 290 | ) | ||||||||
| Net cash flows (used in)/from financing activities | ( 292 | ) | 78,008 | |||||||||
| Net (decrease)/increase in cash and cash equivalents | ( 18,124 | ) | 87,911 | |||||||||
| Cash and cash equivalents at the beginning of the period | 94,296 | 23,469 | ||||||||||
| Effect of exchange rate changes on cash and cash equivalents | 243 | ( 1,287 | ) | |||||||||
| Cash and cash equivalents at the end of the period | 76,415 | 110,093 |
The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.
MEREO BIOPHARMA GROUP PLC
Condensed Consolidated Statements of Changes in Equity
| Notes | Issued capital | Share premium | Other capital reserves | Employee Benefit Trust | Other reserves | Accumulated losses | Translation reserve | Total equity | ||||||||||||||||||||||||||
| '000 | '000 | '000 | '000 | '000 | '000 | '000 | '000 | |||||||||||||||||||||||||||
| At December 31, 2020 | 1,017 | 161,785 | 128,374 | ( 1,305 | ) | 5,001 | ( 309,693 | ) | ( 150 | ) | ( 14,971 | ) | ||||||||||||||||||||||
| Profit for the period | - | - | - | - | - | 12,088 | - | 12,088 | ||||||||||||||||||||||||||
| Other comprehensive income/(loss) | - | - | - | - | - | - | ( 26 | ) | ( 26 | ) | ||||||||||||||||||||||||
| Total | - | - | - | - | - | 12,088 | ( 26 | ) | 12,062 | |||||||||||||||||||||||||
| Share-based payments | - | - | 1,760 | - | - | - | - | 1,760 | ||||||||||||||||||||||||||
| Issuance of share capital, net | 601 | 78,609 | - | - | - | - | - | 79,210 | ||||||||||||||||||||||||||
| Exercise of share options | - | - | ( 108 | ) | 154 | - | - | 46 | ||||||||||||||||||||||||||
| Conversion of warrants | 16 | 158 | - | - | 2,400 | - | - | 2,574 | ||||||||||||||||||||||||||
| At June 30, 2021 | 1,634 | 240,552 | 130,026 | ( 1,151 | ) | 7,401 | ( 297,605 | ) | ( 176 | ) | 80,681 | |||||||||||||||||||||||
| At December 31, 2021 | 1,755 | 247,460 | 129,835 | ( 1,140 | ) | 7,401 | ( 296,968 | ) | ( 341 | ) | 88,002 | |||||||||||||||||||||||
| Loss for the period | - | - | - | - | - | ( 19,158 | ) | - | ( 19,158 | ) | ||||||||||||||||||||||||
| Other comprehensive income/(loss) | - | - | - | - | - | - | ( 1,775 | ) | ( 1,775 | ) | ||||||||||||||||||||||||
| Total | - | - | - | - | - | ( 19,158 | ) | ( 1,775 | ) | ( 20,933 | ) | |||||||||||||||||||||||
| Share-based payments | 9 | - | - | 2,446 | - | - | - | - | 2,446 | |||||||||||||||||||||||||
| Exercise of share options | - | - | ( 82 | ) | 82 | - | - | - | - | |||||||||||||||||||||||||
| Issuance of warrants | - | - | 70 | - | - | - | - | 70 | ||||||||||||||||||||||||||
| At June 30, 2022 | 1,755 | 247,460 | 132,269 | ( 1,058 | ) | 7,401 | ( 316,126 | ) | ( 2,116 | ) | 69,585 |
The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.
MEREO BIOPHARMA GROUP PLC
Notes to the Condensed Consolidated Financial Statements
1. Corporate information
Mereo BioPharma Group plc (the "Company" or "Mereo") is a clinical-stage, United Kingdom ("UK") based biopharmaceutical company focused on rare diseases and oncology.
The Company is a public limited company incorporated and domiciled in the UK, and registered in England, with shares publicly traded on the Nasdaq Global Market via American Depositary Shares ("ADSs") under the ticker symbol MREO. The Company's registered office is located at Fourth Floor, 1 Cavendish Place, London, W1G 0QF, United Kingdom.
These financial statements are the unaudited condensed consolidated financial statements of Mereo BioPharma Group plc and its subsidiaries for the six months ended June 30, 2022. The principal activities of the Company are the development and commercialization of innovative therapeutic pharmaceutical products.
2. Significant accounting policies
Basis of preparation
The unaudited condensed consolidated financial statements for the six-month period ended June 30, 2022 have been prepared in accordance with International Accounting Standards (IAS) 34, Interim Financial Reporting
. These consolidated condensed financial statements do not include all information and disclosures required in the annual financial statements in accordance with International Financial Reporting Standards (IFRS) and should be read in conjunction with the Company's annual consolidated financial statements for the year ended December 31, 2021 filed with the Securities and Exchange Commission ("SEC") on March 31, 2022.
The financial information is presented in pound sterling (" "), which is the presentational currency of the Company. The functional currencies of consolidated subsidiaries are pound sterling and US dollars ("$"). All amounts disclosed in the condensed consolidated financial statements and notes have been rounded to the nearest thousand, unless otherwise stated.
The financial information for the year ended December 31, 2021 has been extracted from the Company's audited financial statements for that year, filed with the SEC on March 31, 2022.
These condensed consolidated financial statements are unaudited and do not constitute statutory accounts of the Company as defined in section 434 of the Companies Act 2006. A copy of the statutory accounts for financial year ended December 31, 2021 has been delivered to the Registrar of Companies. The auditors reported on those accounts and their report was unqualified, did not draw attention to any matters by way of emphasis and did not contain a statement under section 498(2) or (3) of the Companies Act 2006.
Segmental information
The Company has one operating segment. The Chief Operating Decision Maker ("CODM") is the Chief Executive Officer. The Company has a single portfolio of product candidates, with only direct research and development expenses monitored by product candidate. The CODM makes decisions over resource allocation at an overall portfolio level and the Company's financing is managed and monitored on a consolidated basis.
The going concern basis has been applied in these condensed consolidated financial statements as the Company has adequate resources to meet its liabilities as they fall due for the foreseeable future and at least 12 months from the issuance date of these condensed consolidated financial statements.
The Company expects to incur significant operating losses for the foreseeable future as it continues its research and development efforts, seeks to obtain regulatory approval of its product candidates and pursues any future product candidates the Company may develop.
Until such time as the Company can generate significant revenue from product sales, or other commercial revenues, if ever, or through licensing and/or collaboration agreements for its rare disease or oncology product candidates, the Company will seek to finance its operations through a combination of public or private equity or debt financings or other sources.
Summary of significant accounting policies
The accounting policies adopted in the preparation of the condensed consolidated financial statements are consistent with those followed in the preparation of the Company's consolidated financial statements for the year ended December 31, 2021.
Significant accounting estimates and judgments
The preparation of these condensed consolidated financial statements requires the management of the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates and judgments on historical experience and on various other assumptions that it considers to be reasonable. Actual results may differ from these estimates under different assumptions or conditions.
The significant accounting estimates and judgments adopted in the preparation of the condensed consolidated financial statements are consistent with those followed in the preparation of the Company's consolidated financial statements for the year ended December 31, 2021.
The Company recognized upfront proceeds of 36.5 million ($50.0 million) from the license and collaboration agreement with Ultragenyx for setrusumab as revenue in the
period ended June 30, 2021. The variable consideration relating to future milestones and sales royalties will be recognized in the statement of comprehensive income when the milestones are achieved or the underlying commercial sales are made, in the event regulatory approval is obtained.
As a consequence of the license and collaboration agreement with Ultragenyx and in accordance with terms of the 2015 asset purchase with Novartis, the Company made a payment to Novartis of 7.2 million ($10.0 million). The payment included a deduction for costs of 2.4 million which was deferred to be recognized in the statement of comprehensive income when the associated costs are incurred. In the
period ended June 30, 2022, 0.4 million (six months ended June 30, 2021: 0.9 million) of these deductions were recognized within "Cost of revenue" in the condensed consolidated
statement of comprehensive
income. As of June 30, 2022, the remaining balance to be recognized of
0.9 million (June 30, 2021:
1.5 million and December 31, 2021:
1.3 million) is included within "Other liabilities" in the condensed consolidated balance
4. Finance income, finance costs and changes in the fair value of financial instruments
| Six months to June 30, 2022 '000 | Six months to June 30, 2021 '000 | |||||||
| Interest income on short-term deposits | 173 | 1 | ||||||
| Total | 173 | 1 |
| Six months to June 30, 2022 '000 | Six months to June 30, 2021 '000 | |||||||
| Interest on convertible loan notes | ( 1,567 | ) | ( 1,792 | ) | ||||
| Interest on lease liabilities | ( 113 | ) | ( 105 | ) | ||||
| Discounting of provision for deferred cash consideration | ( 163 | ) | ( 72 | ) | ||||
| Other | ( 16 | ) | ( 18 | ) | ||||
| Total | ( 1,859 | ) | ( 1,987 | ) |
Changes in the fair value of financial instruments
| Six months to June 30, 2022 '000 | Six months to June 30, 2021 '000 | |||||||
| Changes in the fair value of warrants - placement | 1,091 | 14,301 | ||||||
| Changes in the fair value of warrants - bank loan | 119 | 62 | ||||||
| Total | 1,210 | 14,363 |
5. Other income and expenses
In February 2022, the Company received a milestone payment of $2.0
million ( 1.5 million)
under the Navi License Agreement with OncXerna. An associated payment was made to the former shareholders of Mereo BioPharma 5, Inc. under the Contingent Value Rights Agreement ("
million ( 0.7 million),
after deductions of costs, charges and expenditures, which resulted in other income, net of 0.8 million.
6. Earnings per share
Basic (loss)/profit per share is calculated by dividing the (loss)/profit attributable for the period to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share is based on dividing the loss attributable for the period, adjusted for the effect of dilutive ordinary shares, by ordinary share equivalents, which includes the weighted average number of ordinary shares outstanding and the effect of dilutive ordinary share equivalents.
| Six months to June 30, 2022 | Six months to June 30, 2021 | |||||||
| Numerator - Basic earnings per share ( '000) | ||||||||
| (Loss)/profit attributable to equity holders of the parent | ( 19,158 | ) | 12,088 | |||||
| Denominator - Basic earnings per share | ||||||||
| Weighted average number of ordinary shares | 583,892,445 | 494,617,344 | ||||||
| (Loss)/profit per share - basic ( ) | ( 0.03 | ) | 0.02 | |||||
| Numerator - Diluted earnings per share ( '000): | ||||||||
| (Loss)/profit attributable to equity holders of the parent | ( 19,158 | ) | 12,088 | |||||
| Effect of dilutive ordinary shares | - | ( 14,363 | ) | |||||
| Numerator - Diluted earnings per share | ( 19,158 | ) | ( 2,275 | ) | ||||
| Denominator - Diluted earnings per share: | ||||||||
| Number of ordinary shares used for basic earnings per share | 583,892,445 | 494,617,344 | ||||||
| Weighted average effect of dilutive ordinary shares | - | 48,264,422 | ||||||
| Weighted average number of diluted ordinary shares outstanding | 583,892,445 | 542,881,766 | ||||||
| Loss per share - diluted ( ) | ( 0.03 | ) | ( 0.00 | ) |
For the period ended June 30, 2021, the effect of dilutive ordinary shares is related to Company's outstanding warrants. For the period ended June 30, 2022, share options, convertible loan notes and warrants were considered to be anti-dilutive as they would have decreased the loss per share and were therefore excluded from the calculation of diluted loss per share. Therefore, the weighted average shares outstanding used to calculate both the basic and diluted loss per share was the same.
7. Property, plant and equipment
| Right-of-use asset (building) | Right-of-use asset (equipment) | Leasehold improvements | Office equipment | IT equipment | Total | |||||||||||||||||||
| '000 | '000 | '000 | '000 | '000 | '000 | |||||||||||||||||||
| Cost or valuation | ||||||||||||||||||||||||
| At January 1, 2022 | 2,903 | 295 | 557 | 173 | 180 | 4,108 | ||||||||||||||||||
| Additions | - | - | - | 7 | 3 | 10 | ||||||||||||||||||
| Currency translation effects | 4 | 6 | - | - | - | 10 | ||||||||||||||||||
| At June 30, 2022 | 2,907 | 301 | 557 | 180 | 183 | 4,128 | ||||||||||||||||||
| Depreciation and impairment | ||||||||||||||||||||||||
| At January 1, 2022 | ( 1,025 | ) | ( 231 | ) | ( 124 | ) | ( 69 | ) | ( 129 | ) | ( 1,578 | ) | ||||||||||||
| Impairment | ( 18 | ) | - | - | - | - | ( 18 | ) | ||||||||||||||||
| Depreciation for the period | ( 309 | ) | ( 41 | ) | ( 47 | ) | ( 11 | ) | ( 10 | ) | ( 418 | ) | ||||||||||||
| At June 30, 2022 | ( 1,352 | ) | ( 272 | ) | ( 171 | ) | ( 80 | ) | ( 139 | ) | ( 2,014 | ) | ||||||||||||
| Net book value | ||||||||||||||||||||||||
| At January 1, 2022 | 1,878 | 64 | 433 | 104 | 51 | 2,530 | ||||||||||||||||||
| At June 30, 2022 | 1,555 | 29 | 386 | 100 | 44 | 2,114 |
8. Intangible assets
| Acquired development programs | ||||
| Cost | '000 | |||
| At January 1, 2022 and June 30, 2022 | 33,005 | |||
| Accumulated revision to estimated value | ||||
| At January 1, 2022 | ( 8,441 | ) | ||
| Revision to estimated value | ( 448 | ) | ||
| At June 30, 2022 | ( 8,889 | ) | ||
| Net book value | ||||
| At January 1, 2022 | 24,564 | |||
| At June 30, 2022 | 24,116 |
The present value of the provision for deferred cash consideration relating to the agreement with AstraZeneca was reviewed at June 30, 2022 (see Note 10
). The change in the period due to changes in timelines or probability of contractual milestones being achieved was a decrease of 0.4
recognized as a reduction of the intangible asset in line with our accounting policies.
During the period the Company did not revise the value of any other intangible assets (2021: nil). As the intangible assets remain under development, no amortization charge has been recognized (2021: nil).
9. Issued capital and reserves
| Number of ordinary shares | Ordinary share capital '000 | Share premium '000 | ||||||||||
| At January 1, 2021 | 338,953,141 | 1,017 | 161,785 | |||||||||
| Issued during the period | 205,557,122 | 617 | 79,001 | |||||||||
| Transaction costs for issued share capital | - | - | ( 234 | ) | ||||||||
| At June 30, 2021 | 544,510,263 | 1,634 | 240,552 | |||||||||
| At January 1, 2022 and June 30, 2022 | 584,908,239 | 1,755 | 247,460 |
Other capital reserves
| Share- based payments | Equity component of convertible loan | Other warrants issued | Merger reserve | Other reserve | Total | |||||||||||||||||||
| '000 | '000 | '000 | '000 | '000 | '000 | |||||||||||||||||||
| At January 1, 2021 | 19,843 | 34,565 | 44 | 40,818 | 33,104 | 128,374 | ||||||||||||||||||
| Share-based payments expense during the period | 1,760 | - | - | - | - | 1,760 | ||||||||||||||||||
| Share option exercise | ( 108 | ) | - | - | - | - | ( 108 | ) | ||||||||||||||||
| At June 30, 2021 | 21,495 | 34,565 | 44 | 40,818 | 33,104 | 130,026 | ||||||||||||||||||
| At January 1, 2022 | 23,026 | 32,843 | 44 | 40,818 | 33,104 | 129,835 | ||||||||||||||||||
| Share-based payments expense during the period | 2,446 | - | - | - | - | 2,446 | ||||||||||||||||||
| Share option exercise | ( 82 | ) | - | - | - | - | ( 82 | ) | ||||||||||||||||
| Issuance of warrants | - | - | 70 | - | - | 70 | ||||||||||||||||||
| At June 30, 2022 | 25,390 | 32,843 | 114 | 40,818 | 33,104 | 132,269 |
Share-based payments
The Company has a share option scheme under which options to subscribe for the Company's shares have been granted to certain executives, non-executive
directors ("NEDs") and employees. The share-based payment reserve is used to recognize (i) the value of equity settled share-based payments provided to employees, including key management personnel, as part of their remuneration and (ii) deferred equity consideration.
The total charge for the six months to June 30, 2022 in respect of all share option schemes was 2.4 million (June 30, 2021: 1.8 million).
During the six months ended June 30, 2022, the Company granted 3,996,400 market value options over ADS under the Mereo 2019 Equity Incentive Plan to certain executives and other employees. The weighted average fair value of options granted was $1.23 per option.
The weighted average exercise price is $1.39 per ADS.
During the same period, the Company granted 507,987 market value options over ADS under the Mereo 2019 NED Equity Incentive Plan to certain non-executive
directors. The weighted average fair value of options granted was $1.10 per option.
The weighted average exercise price is $1.24 per ADS.
Options over ADSs issued during the six months ended June 30, 2022 were valued using the Black-Scholes model with the following weighted average inputs: expected volatility of 96%; risk free interest rate of 1.79%; expected life of 10 years; and market price per ADS of $1.38.
A total of 353,183 deferred restricted stock units, with a weighted average fair value of $1.12 per restricted stock unit,
were also granted in February 2022
under the Mereo 2019 NED Equity Incentive Plan to certain non-executive directors who elected to receive restricted stock units in lieu of their cash fees for the year commencing February 1, 2022.
| June 30, 2022 '000 | December 31, 2021 '000 | |||||||
| Provision for deferred cash consideration | 4,334 | 4,123 | ||||||
| Total | 4,334 | 4,123 | ||||||
| Current | 2,945 | 2,803 | ||||||
| Non-current | 1,389 | 1,320 |
The deferred cash consideration is the estimate of the quantifiable but not certain future cash payment obligations due to AstraZeneca for the acquisition of certain assets. This provision is calculated as the risk adjusted net present value of future cash payments to be made by the Company. The payments are dependent on reaching certain milestones based on the commencement and outcome of clinical trials. The likelihood of achieving such milestones is reviewed at the balance sheet date and increased or decreased as appropriate (see Note 8).
11. Convertible loan notes
| June 30, | December | |||||||
| 2022 | 31, 2021 | |||||||
| '000 | '000 | |||||||
| Novartis Loan Note | 4,094 | 3,771 | ||||||
| Loan Notes - private placement | 11,858 | 10,613 | ||||||
| Total | 15,952 | 14,384 | ||||||
| Current | 15,952 | - | ||||||
| Non-current | - | 14,384 |
Novartis Loan Note is convertible at a fixed price of 0.265 per ordinary share and bears an
interest rate of 6% per annum with a maturity date of February 2023. Loan Notes from the June 2020 private placement are convertible at a fixed price of 0.174
per ordinary share and bears an interest rate
of 6% per annum with a maturity date of June 2023.
12. Warrant liability
| June 30, 2022 '000 | June 30, 2021 '000 | |||||||
| At January 1 | 8,336 | 50,775 | ||||||
| Warrants exercised | - | ( 2,400 | ) | |||||
| Fair value changes during the period | ( 1,210 | ) | ( 14,364 | ) | ||||
| At June 30 | 7,126 | 34,011 |
| June 30, 2022 '000 | December 31, 2021 '000 | |||||||
| Current | 6,904 | - | ||||||
| Non-current | 222 | 8,336 | ||||||
| Total | 7,126 | 8,336 |
The change in fair value of the warrant liability represents an unrealized gain for the six months ended June 30, 2022 and for the six months ended June 30, 2021.